---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Electroconvulsive therapy"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Electroconvulsive therapy. Topics: CANMAT guideline: efficacy, course, and cognitive effects of ECT; VA/DoD guideline: ECT for severe depression; NICE guideline: ECT for severe depression; Meta-analysis of ECT compared with simulated ECT and pharmacotherapy; 5 further topics. 9 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/electroconvulsive-therapy"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Electroconvulsive therapy

<a id="heading-2.2.2.1.7"></a>

## 2.2.2.1.7 Electroconvulsive Therapy

<a id="topic-2.2.2.1.7-1"></a>

### CANMAT guideline: efficacy, course, and cognitive effects of ECT

> “ECT remains one of the most effective treatment options for patients with TRD.”
> “ECT has demonstrated evidence of efficacy and tolerability in the treatment of depressive episodes, with response rates ranging from 65% to 75%”
> “An acute course of ECT usually requires 6 to 12 sessions, with no difference in response outcomes between sessions given twice or thrice weekly”
> “Adverse effects on cognition are of most concern, although modern ECT techniques, including unilateral electrode placement and refined electrical dosing, have reduced both the incidence and severity of cognitive side effects.”
> “Nevertheless, some patients report significant and distressing gaps in autobiographical memory long after ECT, and the discrepancy between cognitive performance and subjective memory dysfunction remains controversial.”
> “Although ECT has high response rates during acute treatment, recurrence occurs in 60% to 80% of patients at 6-month follow-up.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.7-2"></a>

### VA/DoD guideline: ECT for severe depression

> “We recommend offering electroconvulsive therapy (ECT) with or without psychotherapy for patients with severe MDD and any of the following conditions:”
> “A history of a poor response or intolerable side effects to multiple antidepressants”
> “(Strong for | Reviewed, Not changed)”
> “Symptom improvement with ECT is short-term and should be followed by maintenance treatment with antidepressants, or if antidepressants are not tolerated, repeated treatment with ECT.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.7-3"></a>

### NICE guideline: ECT for severe depression

> “Consider electroconvulsive therapy (ECT) for the treatment of severe depression if:”
> “other treatments have been unsuccessful (see the recommendations on further-line treatment).”
> “Make sure people with depression who are going to have ECT are fully informed of the risks, and of the risks and benefits specific to them.”

Source: [NICE (2022)](https://www.nice.org.uk/guidance/ng222/chapter/Recommendations)

<a id="topic-2.2.2.1.7-4"></a>

### Meta-analysis of ECT compared with simulated ECT and pharmacotherapy

> “Real ECT was significantly more effective than simulated ECT (six trials, 256 patients, standardised effect size [SES] -0.91, 95% CI -1.27 to -0.54).”
> “Treatment with ECT was significantly more effective than pharmacotherapy (18 trials, 1144 participants, SES -0.80, 95% CI -1.29 to -0.29).”

Source: [UK ECT Review Group (2003)](https://pubmed.ncbi.nlm.nih.gov/12642045/)

<a id="topic-2.2.2.1.7-5"></a>

### ECT remission after antidepressant pharmacotherapy failure

> “Seven studies were included in this meta-analysis: the overall remission rate amounts to 48.0% (281/585) for patients with and 64.9% (242/373) for patients without previous pharmacotherapy failure.”

Source: [Heijnen et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20814336/)

<a id="topic-2.2.2.1.7-6"></a>

### Network meta-analysis: response with ECT compared with sham

> “bitemporal ECT (summary odds ratio 8.91, 95% confidence interval 2.57 to 30.91), high dose right unilateral ECT (7.27, 1.90 to 27.78)”

Source: [Mutz et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6435996/)

<a id="topic-2.2.2.1.7-7"></a>

### ELEKT-D: ECT compared with intravenous ketamine, including memory outcomes

> “A total of 55.4% of the patients in the ketamine group and 41.2% of those in the ECT group had a response (difference, 14.2 percentage points; 95% confidence interval, 3.9 to 24.2; P<0.001 for the noninferiority of ketamine to ECT).”
> “ECT appeared to be associated with a decrease in memory recall after 3 weeks of treatment (mean [±SE] decrease in the T-score for delayed recall on the Hopkins Verbal Learning Test-Revised, -0.9±1.1 in the ketamine group vs. -9.7±1.2 in the ECT group; scores range from -300 to 200, with higher scores indicating better function) with gradual recovery during follow-up.”

Source: [Anand et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37224232/)

<a id="topic-2.2.2.1.7-8"></a>

### Objective cognitive performance after ECT

> “Twenty-four cognitive variables (84 studies, 2981 patients) were meta-analyzed. No standardized retrograde amnesia tests were identified.”
> “Significant decreases in cognitive performance were observed 0 to 3 days after ECT in 72% of variables”
> “Cognitive abnormalities associated with ECT are mainly limited to the first 3 days posttreatment.”

Source: [Semkovska and McLoughlin (2010)](https://pubmed.ncbi.nlm.nih.gov/20673880/)

<a id="topic-2.2.2.1.7-9"></a>

### Relapse after successful ECT

> “In modern era studies of continuation pharmacotherapy, 51.1% (95% CI=44.7–57.4%) of patients relapsed by 12 months following successful initial treatment with ECT, with the majority (37.7%, 95% CI=30.7–45.2%) relapsing within the first 6 months.”

Source: [Jelovac et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3799066/)

Additional sources: [American Psychiatric Association (2010)](https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
